This article was reviewed by Jeffrey S. Heier, MD
Age-related macular degeneration (AMD) is the leading cause of blindness worldwide.
Dr. Kaiser discusses how risuteganib fared in a phase II trial in patients with intermediate nonexudative AMD.
Eyes with persistent subretinal fluid fared better with visual acuity than eyes that were dry, according to the HARBOR Trial
ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process
David S. Boyer, MD, notes that the goal is to dry every patient out, with undertreatment the leading cause of a loss of visual acuity.
Ganglion, bipolar cells increase options for patients with late-stage retinal disease
The MDA is a nonprofit health organization dedicated to educating and empowering patients with AMD.
Educational format providing pipeline of information about complicated disease By